v3.26.1
Sale of Future Revenue - Narrative (Details) - USD ($)
$ in Thousands
2 Months Ended 3 Months Ended 12 Months Ended 65 Months Ended
Nov. 03, 2020
Dec. 31, 2020
Mar. 31, 2026
Mar. 31, 2025
Jun. 30, 2020
Dec. 31, 2025
Mar. 31, 2026
Disaggregation of Revenue [Line Items]              
Revenues     $ 14,446 $ 8,720      
Royalty              
Disaggregation of Revenue [Line Items]              
Revenues     0     $ 938  
MAM Pangolin Royalty , LLC | Maximum              
Disaggregation of Revenue [Line Items]              
Proceeds from sale of future revenue $ 125,000            
License agreement with Sunovion Pharmaceuticals, Inc.              
Disaggregation of Revenue [Line Items]              
Minimum annual royalty receivable     1,000   $ 1,000   $ 1,000
License agreement with Sunovion Pharmaceuticals, Inc. | Royalty              
Disaggregation of Revenue [Line Items]              
Revenues         $ 8,000    
Monetization Agreement              
Disaggregation of Revenue [Line Items]              
Payments for loan acquisition costs     $ 2,909        
Effective annual interest rate (as a percent) 24.90%            
Monetization Agreement | MAM Pangolin Royalty , LLC              
Disaggregation of Revenue [Line Items]              
Proceeds from sale of future revenue $ 40,000 $ 10,000         $ 50,000
Proceeds from debt, contingent on additional milestones $ 75,000